Zacks Investment Research downgraded shares of PACIRA PHARMACT (PCRX) from OUTPERFORM to NEUTRAL on September 11, 2012, with a target price of $19.70.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PACIRA PHARMACT (PCRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment